Jan. 10, 2025

The U.S. Food and Drug Administration (FDA) seeks public comments on draft guidance it published Jan. 7. Of particular interest to the American College of Radiology® (ACR®) is “Artificial Intelligence (AI)-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations.”

The industry guidance outlines a total product lifecycle (TPLC) approach to risk management of AI device software functions, as well as related documentation to support FDA review. It also provides recommendations relevant to transparency and bias mitigation throughout the TPLC, including within the product’s user interface and labelling.

The ACR Informatics Commission and Data Science Institute® (DSI) leadership are reviewing the guidance. The College’s initiatives related to AI are on the DSI website.

Public comments are due to the FDA by April 7.

If you have questions or would like more information about ACR AI/digital health policy, contact Michael Peters, ACR Senior Director, Government Affairs.


Related ACR News

  • Radiology’s Fight Against Prior Authorization Delays

    ACR is leading national efforts to make prior authorization more efficient and clinically appropriate while reducing the administrative burden and supporting national legislation.

    Read more
  • ACR Supports Medicaid Coverage of Lung Cancer Screening

    ACR-backed bill would mandate Medicaid lung cancer screening, expand cessation coverage, ban prior auth—aiming to save lives and reduce disparities.

    Read more
  • AI-Powered Learning for Smarter Radiology Education

    This article discusses the role of AI in radiology and how AI errors can be reframed as enhanced learning opportunities in radiology education.

    Read more